Breaking News, Financial News

Financial Report: Covance 1Q

Early development revenues were $205.0 million (+7%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Covance 1Q 1Q Revenues: $505.0 million (+9%) 1Q Earnings: $39.1 million (+3%) Comments: Early development revenues were $205.0 million (+7%). Late-stage development revenues were $276.9 million (+11%). The company’s backlog at March 31, 2010 grew 8% to $4.8 billion. Foreign exchange negatively impacted backlog growth by approximately $37 million. Adjusted net orders (adjusted for dedicated capacity contracts) were $490 million in quarter....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters